Jasper Therapeutics Inc (JSPR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
Jasper Therapeutics Inc (JSPR) Competitors
The companies most similar to Jasper Therapeutics are Marker Therapeutics (MRKR), Pluri (PLUR) and Estrella Immunopharma (ESLA). By market cap, Jasper Therapeutics ranks 8th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.
Peer Comparison
JSPR's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics (JSPR) | $15.18M | N/A | 1.6x | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Estrella Immunopharma Inc. (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| Akari Therapeutics PLC (AKTX) | $15.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CEL-SCI Corp (CVM) | $22.51M | N/A | N/A | 0.0% | -109.0% | -62.7% | 0.00% |
| Seres Therapeutics Inc (MCRB) | $14.27M | N/A | 6.6x | 0.0% | N/A | 68.9% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Quoin Pharmaceuticals Ltd DRC (QNRX) | $17.78M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Passage Bio Inc (PASG) | $13.68M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $15.64M | N/A | 6.6x | 0.0% | -390.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Jasper Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Estrella Immunopharma Inc. (ESLA) | Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. | ESLA competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| Akari Therapeutics PLC (AKTX) | Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory... | AKTX competitors |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| CEL-SCI Corp (CVM) | CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. | CVM competitors |
| Seres Therapeutics Inc (MCRB) | Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally... | MCRB competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Quoin Pharmaceuticals Ltd DRC (QNRX) | Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases... | QNRX competitors |
| Passage Bio Inc (PASG) | Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. | PASG competitors |
Frequently Asked Questions About JSPR
Who are Jasper Therapeutics' main competitors?
The companies most similar to Jasper Therapeutics include Marker Therapeutics (MRKR), Pluri (PLUR), Estrella Immunopharma (ESLA), Plus Therapeutics (PSTV) and Tscan Therapeutics (TCRX), listed from the closest match.
Who is Jasper Therapeutics' biggest competitor?
Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Marker Therapeutics (MRKR) is the closest match by business profile, size, sector and industry.
How does JSPR stock compare with its competitors?
JSPR's P/S is 1.6x against a peer median of 6.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Jasper Therapeutics' competitors pays a higher dividend?
Jasper Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Jasper Therapeutics bigger than its competitors?
No. Jasper Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.
JSPR pages: Overview, Earnings, Forecast, Financials, Competitors